Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26501075 | 0.82 | CYP19A1 (0.33) | HDAC1 | |
| SCHEMBL26501071 | 0.80 | GGPS1 (0.36) | HDAC1 | |
| SCHEMBL26501114 | 0.80 | HDAC1 (0.34) | HDAC1 | |
| SCHEMBL25110303 | 0.79 | CYP19A1 (0.41) | GBA1 | |
| SCHEMBL22794227 | 0.79 | ALDH1A1 (0.49) | OPRM1OPRD1OPRK1GBA1 | |
| SCHEMBL26501115 | 0.78 | NAMPT (0.39) | NAMPT | |
| SCHEMBL29307652 | 0.76 | DDX3X (0.37) | HDAC1NAMPT | |
| SCHEMBL22803403 | 0.75 | DGAT1 (0.40) | — | |
| SCHEMBL25110987 | 0.73 | GBA1 (0.43) | GBA1 | |
| SCHEMBL24713570 | 0.73 | POLB (0.43) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | HDAC1 2570/4885OPRM1 4409/4885OPRD1 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.